NA-PHER2 was a neoadjuvant trial of HER2-targeted trastuzumab and pertuzumab plus the CDK4/6 inhibitor palbociclib with or without endocrine therapy in HER2-positive, ER-positive breast cancer. Here the authors report biomarkers predictive of pathological response and treatment-induced molecular changes in patients from the trial.
- Maurizio Callari
- Matteo Dugo
- Giampaolo Bianchini
